Skip to main content

Advertisement

Table 2 Results

From: Cost-effectiveness of ceftolozane/tazobactam plus metronidazole versus piperacillin/tazobactam as initial empiric therapy for the treatment of complicated intra-abdominal infections based on pathogen distributions drawn from national surveillance data in the United States

Summary of results Ceftolozane/tazobactam + metronidazole Piperacillin/tazobactam Incremental Ceftolozane/tazobactam + metronidazole - Piperacillin/tazobactam
Total costs per patient $44,226 $44,811 -$585
Total life years per patient (undiscounted) 21.75 21.50 0.25
Total QALYs per patient (undiscounted) 18.49 18.27 0.22
Total QALYs per patient (discounted) 12.85 12.70 0.15
Incremental Cost Effectiveness Ratio (Cost per discounted QALY saved) Dominant
Hospitalization days saved per-patient 0.63
Distribution of patients based on empiric treatment    
 Resistant to initial therapy (%) 35.2 48.8
 Susceptible to initial therapy (%) 64.8 51.2
Costs    
 Hospital costs per patient $15,468 $17,069 -$1601
 Drug costs per patient $818 $196 $622
 Lifetime health care expenditure per patient $27,940 $27,546 $394
  1. QALY Quality Adjusted Life Year, IAAT Initial appropriate antibiotic therapy, IIAT Initial inappropriate antibiotic therapy